Novel targets for treatment of adult acute lymphocytic leukemia.
Publication/Presentation Date
10-1-2010
Abstract
The treatment of acute lymphocytic leukemia (ALL) results in long-term disease-free survival in only 30-40% of adults. Conventional chemotherapy is toxic and woefully ineffective. Therefore, novel agents are being investigated. Among these agents are monoclonal antibodies such as rituximab, epratuzumab, and alemtuzumab and targeted therapies such as tyrosine kinase inhibitors, mTOR inhibitors, and mitogen-activated protein kinase (MEK) inhibitors. This article discusses such novel targets for the treatment of ALL.
Volume
5
Issue
4
First Page
207
Last Page
212
ISSN
1558-822X
Published In/Presented At
Kasner M. T. (2010). Novel targets for treatment of adult acute lymphocytic leukemia. Current hematologic malignancy reports, 5(4), 207–212. https://doi.org/10.1007/s11899-010-0064-8
Disciplines
Medicine and Health Sciences
PubMedID
20680526
Department(s)
Hematology-Medical Oncology Division
Document Type
Article